New oral drug targets Tough-to-Treat leukemia
NCT ID NCT07084584
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental oral drug called GB3226 in adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug works by blocking two pathways that help leukemia cells grow. The study aims to find a safe dose and check for signs that the drug is shrinking or controlling the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GB3226
- What this could lead to
- If successful, this could provide a new oral treatment option for people with AML that has not responded to standard therapies.
- What could go wrong
- This is an early Phase 1 trial, so safety and dosing are still being established. The drug may not prove effective or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Off-the-Shelf immune cells take aim at Hard-to-Treat leukemia
- Can lab tests guide better AML treatment choices?
- New hope for tough leukemia: experimental therapy CT1390B enters first human tests
- Experimental CAR-T therapy targets tough leukemia
- New drug CLN-049 aims to fight Hard-to-Treat blood cancers
- Experimental CAR-T therapy takes on tough leukemia